Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) Shares Outstanding: 2.04

Is Bristol-Myers Squibb Company’s shares outstanding high or low?

Bristol-Myers Squibb Company's shares outstanding of 2.04 is in line with its 5-year average of 2.12, near the low end of its 5-year range (2.03–2.26).

The shares outstanding for Bristol-Myers Squibb Company (BMY) is 2.04. It is above its 12-month average by 0.34% (2.03).

BMY Shares Outstanding Chart

BMY Shares Outstanding
2.04+0.69% 1Y
Zoom

BMY Average Shares Outstanding Chart

BMY Current vs Average Shares Outstanding Chart

BMY Shares Outstanding Metrics

SHARES OUTSTANDING

2.04

SHARES OUTSTANDING AVG TTM

2.03

SHARES OUTSTANDING AVG 3Y

2.07

SHARES OUTSTANDING AVG 5Y

2.12

SHARES OUTSTANDING AVG 10Y

1.92

SHARES OUTSTANDING AVG 15Y

1.84

SHARES OUTSTANDING AVG 20Y

1.87

CURRENT VS TTM AVG

+0.34%

CURRENT VS 3Y AVG

-1.25%

CURRENT VS 5Y AVG

-3.92%

CURRENT VS 10Y AVG

+6.57%

CURRENT VS 15Y AVG

+10.88%

CURRENT VS 20Y AVG

+9.11%

Share Structure

Shares Outstanding

2.04B

Float Shares

N/A

Stock Price

$56.48

Market Cap

$115.3B

Annual Shares Outstanding History

YearWeighted Average SharesYoY Change
20252.04B+0.69%
20242.03B-2.03%
20232.07B-2.86%
20222.13B-4.10%
20212.22B-1.64%
20202.26B+32.43%
20191.71B+4.41%
20181.63B-0.73%
20171.65B-1.56%
20161.67B+0.24%
20151.67B+0.60%
20141.66B+0.79%
20131.64B-1.56%
20121.67B-1.76%
20111.70B-0.76%
20101.71B-13.22%
20091.97B-0.15%
20081.98B+0.36%
20071.97B+0.51%
20061.96B+0.41%
20051.95B+0.51%
20041.94B+0.26%
20031.94B-3.01%
20022.00B+2.95%
20011.94B-1.27%
20001.97B-0.96%
19991.98B-0.15%
19981.99B-0.25%
19971.99B-0.80%
19962.01B-

Relationship: Market Cap = Shares Outstanding × Stock Price

Key concepts:

  • Float shares: Shares available for public trading
  • Dilution: When new shares are issued, existing shareholders own less
  • Buybacks: Reduce share count, increasing EPS and ownership stake
  • Stock splits: Increase share count but don't change market cap

Bristol-Myers Squibb Company Shares Outstanding Formula & Definition

Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company Shares Outstanding FAQ

What is the shares outstanding for Bristol-Myers Squibb Company (BMY)?
The shares outstanding for BMY stock is 2.04.
Is Bristol-Myers Squibb Company's shares outstanding high or low?
Bristol-Myers Squibb Company's shares outstanding of 2.04 is in line with its 5-year average of 2.12, near the low end of its 5-year range (2.03–2.26).
What is the TTM average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The TTM average shares outstanding for BMY stock is 2.03.
What is the 3Y average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The 3Y average shares outstanding for BMY stock is 2.07.
What is the 5Y average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The 5Y average shares outstanding for BMY stock is 2.12.
What is the 10Y average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The 10Y average shares outstanding for BMY stock is 1.92.
What is the 15Y average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The 15Y average shares outstanding for BMY stock is 1.84.
What is the 20Y average shares outstanding for Bristol-Myers Squibb Company (BMY)?
The 20Y average shares outstanding for BMY stock is 1.87.

Bristol-Myers Squibb Company Shares Outstanding History

DATESHARES OUTSTANDING
2025-12-312.04
2024-12-312.03
2023-12-312.07
2022-12-312.13
2021-12-312.22
2020-12-312.26
2019-12-311.71
2018-12-311.63
2017-12-311.65
2016-12-311.67
2015-12-311.67
2014-12-311.66
2013-12-311.64
2012-12-311.67
2011-12-311.70
2010-12-311.71
2009-12-311.97
2008-12-311.98
2007-12-311.97
2006-12-311.96
2005-12-311.95
2004-12-311.94
2003-12-311.94
2002-12-312.00
2001-12-311.94
2000-12-311.97
1999-12-311.98
1998-12-311.99
1997-12-311.99
1996-12-312.01

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner